Seaport Therapeutics CEO Daphne Zohar at the Endpoints 11 gala (Michael Last Photography)

For­mer Karuna crew quick­ly as­sem­bles $225M for next neu­ro bet at Sea­port

The team at Sea­port Ther­a­peu­tics, a Boston neu­ropsy­chi­a­try biotech, is hav­ing a good fall sea­son.

Sea­port said Mon­day it has pieced to­geth­er $225 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.